Ballew Advisors, Inc Ginkgo Bioworks Holdings, Inc. Transaction History
Ballew Advisors, Inc
- $141 Million
- Q2 2024
A detailed history of Ballew Advisors, Inc transactions in Ginkgo Bioworks Holdings, Inc. stock. As of the latest transaction made, Ballew Advisors, Inc holds 20,000 shares of DNA stock, worth $154,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,000
Previous 11,000
81.82%
Holding current value
$154,200
Previous $12,000
50.0%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding DNA
# of Institutions
344Shares Held
925MCall Options Held
1.04MPut Options Held
2.23M-
Viking Global Investors LP143MShares$1.1 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA139MShares$1.07 Billion0.0% of portfolio
-
Baillie Gifford & CO134MShares$1.04 Billion0.04% of portfolio
-
Anchorage Capital Group, L.L.C. New York, NY69.9MShares$539 Million7.28% of portfolio
-
Black Rock Inc. New York, NY42MShares$324 Million0.0% of portfolio
About Ginkgo Bioworks Holdings, Inc.
- Ticker DNA
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 1,287,779,968
- Market Cap $9.93B
- Description
- Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agric...